logo-loader
RNS
Synairgen PLC

Synairgen plc - Result of General Meeting and Total Voting Rights

RNS Number : 6572T
Synairgen plc
16 January 2025
 

 


Synairgen plc

('Synairgen' or the 'Company')

Result of General Meeting and Total Voting Rights

 


Southampton, UK - 16 January 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that, at the General Meeting held earlier today, all resolutions as set out in the Circular dated 20 December 2024, were duly passed by shareholders on a poll.

A summary of the votes received for the General Meeting will be made available shortly on the Company's website at https://www.synairgen.com/investors/aim-rule-26.

Accordingly, the Company has raised total gross proceeds of £18 million from the Subscription by TFG Asset Management (on behalf of the Relevant Funds).

Application has been made for a total of 900,000,000 New Ordinary Shares to be issued pursuant to the Subscription, to be admitted to trading on AIM.  It is expected that Admission and dealings in the 900,000,000 New Ordinary Shares will commence at 8.00 a.m. on 17 January 2025.

Following Admission, the Company's issued ordinary share capital will comprise 1,102,660,697 Ordinary Shares, none of which are held in treasury. The above figure of 1,102,660,697 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

As detailed in the Results of Non-Underwritten Fundraising announcement on 15 January 2025, as the Minimum Fundraising Condition was not met the Company intends to apply for the cancellation of its Ordinary Shares from trading on AIM ("Cancellation"). A separate announcement will be made in this regard and a circular will be posted to Shareholders in due course which will contain details of the proposed Cancellation.

Following the conclusion of the General Meeting, Martin Murphy has been appointed as an independent Non-Executive Director of the Company. See separate announcement issued today announcing Martin's appointment.

This announcement should be read in conjunction with the full text of the Circular posted to Shareholders on 20 December 2024, copies of which are available on the Company's website. The same definitions apply throughout this announcement as are applied in the Circular.

For further enquiries, please contact:

Synairgen plc

+ 44 (0)23 8051 2800

Media@synairgen.com


Cavendish Capital Markets Limited -
Nominated Adviser, joint broker and sole bookrunner

+ 44 (0)20 7220 0500

Geoff Nash/Camilla Hume/Trisyia Jamaludin


ICR Healthcare (Financial Media and Investor Relations)

+44 (0)20 3709 5700

Mary-Jane Elliott/Namrata Taak/Lucy Featherstone
synairgen@icrhealthcare.com


 

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMPKABNPBKDNDD
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read